Abbott Laboratories shares were down Wednesdsay morning after the company laid out guidance for the first quarter of the year ...

Abbott Laboratories posted lower-than-expected sales in its latest quarter, dented in part by diminished demand for Covid-19 testing-related products. The healthcare-products manufacturer logged ...

The FDA granted marketing clearances for infectious disease tests, updates to a digital pathology system, and immunoassays for chronic diseases.

Excluding COVID-19 testing-related sales, growth in Rapid Diagnostics was driven by strong demand for Abbott’s portfolio of respiratory disease tests. Guidance: Abbott projects full-year 2025 ...